Literature DB >> 16807741

[Current pathophysiological aspects of systemic sclerosis].

T Krieg1, N Hunzelmann.   

Abstract

Systemic scleroderma is characterized by a chronic inflammatory process of unknown etiology resulting in an increased deposition of connective tissue proteins in the involved organs. Involvement of the vascular system and the resulting fibrosis lead to atrophy and malfunction of the involved internal organs and the skin. Due to the development of new therapeutic concepts in particular with regard to the vascular involvement, the interaction between the vascular system and the connective tissue moves increasingly into focus. This review describes the major advancemades during recent years for the understanding of the pathophysiology of systemic scleroderma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16807741     DOI: 10.1007/s00393-006-0066-z

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  26 in total

1.  Circulating collagen metabolites in systemic sclerosis. Differences between limited and diffuse form and relationship with pulmonary involvement.

Authors:  A Scheja; M Wildt; F A Wollheim; A Akesson; T Saxne
Journal:  Rheumatology (Oxford)       Date:  2000-10       Impact factor: 7.580

2.  Defective vasculogenesis in systemic sclerosis.

Authors:  Masataka Kuwana; Yuka Okazaki; Hidekata Yasuoka; Yutaka Kawakami; Yasuo Ikeda
Journal:  Lancet       Date:  2004 Aug 14-20       Impact factor: 79.321

3.  Identification of fetal DNA and cells in skin lesions from women with systemic sclerosis.

Authors:  C M Artlett; J B Smith; S A Jimenez
Journal:  N Engl J Med       Date:  1998-04-23       Impact factor: 91.245

4.  Circulating type I collagen degradation products: a new serum marker for clinical severity in patients with scleroderma?

Authors:  N Hunzelmann; J Risteli; L Risteli; C Sacher; R Vancheeswaran; C Black; T Krieg
Journal:  Br J Dermatol       Date:  1998-12       Impact factor: 9.302

Review 5.  Scleroderma epidemiology.

Authors:  Maureen D Mayes
Journal:  Rheum Dis Clin North Am       Date:  2003-05       Impact factor: 2.670

Review 6.  Transgenic analysis of scleroderma: understanding key pathogenic events in vivo.

Authors:  Christopher P Denton; David J Abraham
Journal:  Autoimmun Rev       Date:  2004-06       Impact factor: 9.754

Review 7.  Serological assessment of type I collagen burden in scleroderma spectrum disorders: a systematic review.

Authors:  M Dziadzio; R E Smith; D J Abraham; R J Stratton; A Gabrielli; C M Black; C P Denton
Journal:  Clin Exp Rheumatol       Date:  2004 May-Jun       Impact factor: 4.473

8.  Significant correlation between connective tissue growth factor gene expression and skin sclerosis in tissue sections from patients with systemic sclerosis.

Authors:  A Igarashi; K Nashiro; K Kikuchi; S Sato; H Ihn; G R Grotendorst; K Takehara
Journal:  J Invest Dermatol       Date:  1995-08       Impact factor: 8.551

9.  Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers.

Authors:  Oliver Distler; Angela Del Rosso; Roberto Giacomelli; Paola Cipriani; Maria L Conforti; Serena Guiducci; Renate E Gay; Beat A Michel; Pius Brühlmann; Ulf Müller-Ladner; Steffen Gay; Marco Matucci-Cerinic
Journal:  Arthritis Res       Date:  2002-08-30

10.  Overexpression of cathepsin K during silica-induced lung fibrosis and control by TGF-beta.

Authors:  Sybille van den Brûle; Pierre Misson; Frank Bühling; Dominique Lison; François Huaux
Journal:  Respir Res       Date:  2005-07-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.